Cargando…
Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
Uveal melanoma (UM) has a high risk to progress to metastatic disease with a median survival of 3.9 months after metastases detection, as metastatic UM responds poorly to conventional and targeted chemotherapy and is largely refractory to immunotherapy. Here, we present a patient-derived zebrafish U...
Autores principales: | Groenewoud, Arwin, Yin, Jie, Gelmi, Maria Chiara, Alsafadi, Samar, Nemati, Fariba, Decaudin, Didier, Roman-Roman, Sergio, Kalirai, Helen, Coupland, Sarah E., Jochemsen, Aart G., Jager, Martine J., Engel, Felix B., Snaar-Jagalska, B. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272172/ https://www.ncbi.nlm.nih.gov/pubmed/37321991 http://dx.doi.org/10.1038/s41420-023-01446-6 |
Ejemplares similares
-
Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery
por: Yin, Jie, et al.
Publicado: (2023) -
Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023) -
XePhIR: the zebrafish xenograft phenotype interactive repository
por: Groenewoud, A, et al.
Publicado: (2022)